Definitive Proxy Statement
Teva clinical trial transparency and disclosure policy - July 8, 2019
Teva refiles long-acting schizophrenia drug after FDA rejection
Today, Teva... - Teva Pharmaceutical Industries Ltd. | Facebook
Thomas Thoma | Clinical Trials Europe
ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business
Teva wins first date to market generic Linzess in the USA
Regeneron and Teva Face FDA Hold On Chronic Pain Clinical Trial - Xtalks
Teva Pharmaceuticals Found Liable in Landmark Opioid Trial - The New York Times
Is Teva late reporting EU clinical trials?
Julie Mathena - Director, Global Medical Affairs - Teva Pharmaceuticals | LinkedIn
Teva USA
Teva takes 2nd long-acting schizophrenia drug into phase 3
Teva Announces Positive Top-Line Results from AJOVY® (fremanezumab) Clinical Trials in Japan | International Business
EX-99.1
Insilico collaborates with Teva on AI system | EurekAlert!
IBM, Teva to Use A.I. for Drug Repurposing Program - Drug Discovery and Development
Big data emphasis underpins Teva's plans for smart inhaler, clinical trial innovations | MobiHealthNews
Reslizumab Reslizumab (Teva) | Bioz | Ratings For Life-Science Research
/cloudfront-us-east-2.images.arcpublishing.com/reuters/G5JWOXLOQZIDLHFUUAR3HXPXEQ.jpg "Teva to pay $523 mln to New York as it looks to move past opioid lawsuits | Reuters")
Teva to pay $523 mln to New York as it looks to move past opioid lawsuits | Reuters
Momenta: Novartis capable of countering Teva's Copaxone protectionism
